Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 100 of 3499 entries
View as:

Human Papillomavirus Epidemiology in Nigeria

Phase: N/A Priority: Normal
NCT ID: NCT00804466 Org: User:
Start: 07/06/09 End: 11/10/20 Due: 11/10/21

Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00965250 Org: User:
Start: 08/31/09 End: 06/30/16 Due: 06/30/17

Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium

Phase: N/A Priority: Normal
NCT ID: NCT00363883 Org: User:
Start: 06/30/06 End: 12/31/10 Due: 12/31/11

Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00072566 Org: User:
Start: 12/31/03 End: 11/30/08 Due: 11/30/09

Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01420926 Org: User:
Start: 11/16/11 End: 04/01/21 Due: 04/01/22

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT03092674 Org: User:
Start: 02/02/18 End: 06/26/24 Due: 06/26/25

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03939897 Org: User:
Start: 06/17/20 End: 10/04/24 Due: 10/04/25

Evaluation and Natural History of Children With Cancer and AIDS

Phase: N/A Priority: Normal
NCT ID: NCT00001424 Org: User:
Start: 11/30/94 End: 08/31/00 Due: 08/31/01

Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00055861 Org: User:
Start: 07/31/02 End: - Due: -

Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00006486 Org: User:
Start: 10/31/00 End: - Due: -

Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00100841 Org: User:
Start: 11/30/04 End: 07/31/11 Due: 07/31/12

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00070499 Org: User:
Start: 08/15/04 End: 03/10/26 Due: 03/10/27

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00061945 Org: User:
Start: 06/30/03 End: 10/31/12 Due: 10/31/13

Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01238211 Org: User:
Start: 12/14/10 End: 03/15/21 Due: 03/15/22

EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00114738 Org: User:
Start: 06/15/05 End: 08/11/22 Due: 08/11/23

Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT02568566 Org: User:
Start: 05/19/16 End: 01/10/26 Due: 01/10/27

Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT01016015 Org: User:
Start: 11/30/09 End: 07/31/14 Due: 07/31/15

(1)H-Nuclear Magnetic Resonance Spectroscopic Imaging of the Brain in Patients Who Receive Neurotoxic Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00001807 Org: User:
Start: 04/16/99 End: 04/18/19 Due: 04/18/20

Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)

Phase: N/A Priority: Normal
NCT ID: NCT04358107 Org: User:
Start: 04/20/20 End: 12/31/26 Due: 12/31/27

Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT00383760 Org: User:
Start: 08/31/06 End: 07/31/11 Due: 07/31/12

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Phase: N/A Priority: Normal
NCT ID: NCT02821754 Org: User:
Start: 07/05/16 End: 12/31/22 Due: 12/31/23

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Phase: N/A Priority: Normal
NCT ID: NCT03213665 Org: User:
Start: 11/13/17 End: 12/31/24 Due: 12/31/25

18F-DCFPyL PET/CT in Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05009979 Org: User:
Start: 01/18/23 End: 11/20/24 Due: 11/20/25

FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00383565 Org: User:
Start: 09/30/06 End: 04/30/11 Due: 04/30/12

Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus

Phase: N/A Priority: Normal
NCT ID: NCT00378911 Org: User:
Start: 10/31/06 End: 01/31/10 Due: 01/31/11